MKHD is Our New Smoking Hot Pick!!
MKHD is a GROUND FLOOR OPPORTUNITY at the current pps!
Company: Mount Knowledge USA Inc. (OTCBB: MKHD)
Current PPS: $0.20-0.22
Website: www.MountKnowledge.com
Mount Knowledge™ is an educational software development, sales and training company offering innovative and proprietary learning software products and teaching services.
The Company has developed a suite of market specific “real-time self learning” software applications for both corporate and direct consumer markets worldwide.
Mount Knowledge™ products and services are changing the way consumers of all ages are learning and retaining subjects starting at childhood and continuing for the rest of their personal and corporate learning lives.
The Company’s software learning tools and teaching methodologies are currently being offered in China to the more than 300 million students, from grade school to university, seeking to learn English, including the vast number of people in the Chinese workplace increasing their English fluency to achieve greater income earning potential.
Highlights
- The Company currently has offices in 7 Major Cities across the world located in the US, Canada, Hong Kong and Mainland China.
- Technology stems from an interactive and visual learning system
- Global learning software market growing at a 15% to 30% year-over-year*
- China’s English language learning industry is estimated at $5.6B in 2010 with potential significant growth over the coming decade*
- Asian market expected to reach CAGR of 25% to 30% through 2010*
- A new report by Global Industry Analysts forecasts the global e-learning market will reach $107.3bn by 2015
Mount Knowledge’s Learning Features include:
- Integrated English Real Time Learning System
- Automatically Generates an Infinite Number of Lessons & Exercises
- Personal Teacher For Life – All Levels Of English
- Adapts To User’s Learning Needs And Knowledge Level
- Totally Flexible – Different Learning Styles
- TOEFL/IELTS Preparation Tests (New)
- Text-To-Visual: Syntality™ ESL Training Methodology
Share Structure
|
||
Growth Strategy
We believe the Company is well positioned to become the standard for accelerated learning products and training services. The Company has a four-part strategy for growth:
- Accelerated Acquisition Strategy – acquiring approximately one or more acquisition target entities before year-end 2011, subject to market conditions, suitable acquisition targets, and available financing. The Company will first target the vast English learning China market and other Asian territories in 2011, with a long-term vision of expanding into other world markets in 2012.
- Learning Centers and Schools - providing co-marketing and partnership licensing of language learning products and services to existing learning centers and schools in China and throughout Asia offering students the latest in interactive learning technology to create an exceptional educational experience and value to each student.
- English Language Learning / Training - providing language learning and training services to major corporations, schools and government offices with a blended approach of on-site training and the use of Mount Knowledge software to provide online tools and custom content development in a licensing revenue model (B2B and B2C).
- Web-based Applications - providing browser-based and mobile software applications to allow online connectivity (e-portal) to Mount Knowledge™ learning tools and to foster interaction among users (online community).
Employees
Currently, they have over 60 employees in the Company, including employees in US, Canada, China and Hong Kong.
The team’s brief biographies follow:
Erwin E. Sniedzins, Chairman , Founder and Chairman of Mt. Knowledge Inc and Mount Knowledge USA, Inc. – Mr. Sniedzins has held senior management positions at Xerox with extensive sales/marketing and business development and new product launch experience. He created Mount Knowledge™, with patent pending Knowledge Generator ™, Real Time Self-Learning™; in 2001 he created an unique marketing interactive software product, selling 50,000 CDs to Sears (Eatons) and 30,000 CDs to Unilever (Lipton’s); organized, in 1991, a Mt. Everest expedition to raise International awareness and $1.1 M for Rett Syndrome; created a National Everfitness program that went out to 18,000 schools in Canada; authored, produced and published a best seller, “Who’s Who in Toronto: A Celebration of this City ”;
Daniel Carr – CEO and President of Mount Knowledge USA, Inc. and Director of Auror Capital Corp. – Mr. Carr has over 30 years of experience and leadership, including financial positions in over 14 companies providing hi-tech development, manufacturing, wholesale distribution, on-line financial services, and IT infrastructure.
Simon Arnison – CTO and Director of Mt. Knowledge Inc and Mount Knowledge USA, Inc. – Mr. Arnison has over 23 years of executive and management experience in the software, multimedia, educational products and PC marketplace in both Europe and North America, and is former founder and CEO of Classwave Wireless, and former founder and CTO of Innotech. Mr. Arnison has been a pioneer and visionary in the wireless and Java marketplace and has written and presented on these fields for various publications and events.
Please remember to do your due diligence. To view our full disclaimer please click here
HIDE at First Glimpse- An Early Penny Pick Alert
HIDE at First Glimpse
Early Penny Pick Alert (Pk)
HIDE was brought to our attention from the increasing activity that we noticed over the past few weeks. After doing our DD and looking over the chart we feel positive that HIDE could make a major move to the upside very soon. We highly suggest that everyone do their research on this hidden gem and keep a very close eye on it in the mean time.
With over 100 years of combined telecom experience, Nucentcom Inc has established undisputable trust and long lasting relationships with numerous corporations across the globe. To meet the demands of a constantly changing global market, Nucentcom Inc’s world class customer service representatives are multilingual and operate 24/7.
About HIDE (Nucentcom Inc)
Nucentcom, Inc. is a state-of-the-art, facilities-based telecommunications and technology company specializing in providing retail, wholesale (carrier’s carrier) and other telecommunications services to carriers and subscribers in North America, Europe and Asia through the innovative use of proven technologies. Our proprietary call-processing methodology and innovative technology enable the deployment of a variety of revenue-generating services. To date the company has focused on three areas of telecommunications:
Retail Telecommunication Services – In addition to Broadband dial tone and dial around retail products, Nucentcom is creating a private VoIP network for its UPASS-Enabled Homepage with E-Commerce subscribers, whereby individuals in different countries will be able to make high quality calls to each other, for one low, monthly fixed cost.
Wholesale Carrier Solutions – Nucentcom offers wholesale services through our worldwide network to carriers, telephony resellers and others around the world by operating through various Interconnection Agreements with Telecommunication Authorities in India, Pakistan, the Middle East and Latin America.
Municipal NuMAX Networks – Nucentcom has developed a system to work with municipalities to construct a wireless network that would allow broadband internet access and other ancillary services throughout the municipality.
Nucentcom Inc Leading Platforms Support the Following Applications:
• Prepaid and Post Paid Long Distance Calling Services including traditional card-based, ANY-authenticated, and real-time rated “Bucket-of-Minutes” implementations for integration with your existing Class 5 Broadband Telephony Services
• Highly Scalable Reservation-less Audio Conferencing Services
• Voice Mail and Unified Messaging
• Full featured Class 5 Residential and Business Broadband Telephony
• Web based applications and services
Our platform provides the carrier-grade scalability and high availability needed for network-hosted Services connected to SIP or H323 enabled PSTN-to-IP Media Gateways or Session Border Controllers. This full featured SDP environment – Solaris/Linux based – includes a standards-based Application Server, Media Server, and a graphically customizable portal.
Link to HIDE’s Chart
Please remember to do your due diligence. To view our full disclaimer please click here
BullQuake- ZIPZ, LVCA, & AEZS Afternoon Recap
We first alerted ZIPZ to our members at 0.0005 yesterday afternoon. Since our alert ZIPZ has Bullishly Roared up Over 100%, testing 0.0013 for the HOD.
LVCA- We alerted this one premarket, during mid afternoon LVCA had already made our members over 12%.
AEZS- We alerted our members on Twitter mid at 1.57 about the potential for a rebound, since then AEZS has climbed to a high of 1.77! We firmly believe AEZS could start a bullish uptrend headed into the ASCO, which is scheduled for early June.
Please remember to do your due diligence. To view our full disclaimer please click here
Breaking News: (AEZS) Aeterna Zentaris: Data on Lead Anticancer Compounds Perifosine and AEZS-108 to be Presented at Upcoming ASCO Annual Meeting
QUÉBEC CITY, May 21 /PRNewswire-FirstCall/ – Aeterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), (the “Company”) a late-stage drug development company specialized in oncology and endocrine therapy, today announced that data on two of its lead anticancer compounds, perifosine and AEZS-108, will be presented at the upcoming Annual Meeting of the American Society of Clinical Oncology (ASCO), which will be held June 4 through 8, 2010 at McCormick Place in Chicago. Two posters on perifosine, Aeterna Zentaris’ novel, potentially first-in-class, oral anticancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, will be presented in pediatric solid tumors and colorectal cancer. A poster will also be presented on the Company’s doxorubicin targeted conjugate compound, AEZS-108, in ovarian cancer.
Abstracts selected for presentation are as follows:
Perifosine
----------
Abstract # 9540: "Phase I Study of Single Agent Perifosine for
Recurrent Pediatric Solid Tumors"
Lead Author: Oren J. Becher, MD, Memorial Sloan-Kettering Cancer
Center
Presenter: Mark Kieran, MD, PhD, Dana-Farber Cancer Institute
Date and Time: Sunday, June 6, 2010, 2 pm-6 pm (poster discussion
5:40pm-6pm)
Poster Board #: 42b
Location: S Hall A2 (poster discussion in S504)
Abstract # 3531: "Final results of a randomized Phase II study of
perifosine in combination with capecitabine (P-CAP)
vs. placebo plus capecitabine (CAP) in patients (pts)
with second or third line metastatic colorectal
cancer (mCRC)"
Lead Author: Donald A. Richards, MD, PhD, Texas Oncology
Presenter: Wells Messersmith, MD, University of Colorado
Date and Time: Tuesday, June 8, 2010, 8 am-12 noon (poster
discussion 11:45 am-12 noon)
Poster Board #: 22
Location: S403 (poster discussion in S406)
AEZS-108
--------
Abstract # 5035: "Phase 2 study of AEZS-108, a targeted cytotoxic LHRH
analog, in patients with LHRH receptor positive
platinum resistant ovarian cancer"
Lead Author: Prof. Günter Emons, Chairman, Department of
Obstetrics & Gynaecology Georg-August University
Gottingen, Germany
Presenter: Prof. Günter Emons
Date and Time: Saturday, June 5, 2010 2pm- 6pm
Poster Board #: 45B
Location: S Hall A2
Copies of these abstracts are currently available and can be viewed on-line through the ASCO website: www.asco.org.
About Perifosine
Perifosine, a novel, potentially first-in-class, oral Akt inhibitor, is currently in Phase 3 trials for multiple myeloma and advanced colorectal cancer, under Special Protocol Assessment and Fast Track designation granted by the Food and Drug Administration (FDA) for both indications. FDA has also granted perifosine orphan-drug status for multiple myeloma. Furthermore, the European Medicines Agency (EMA) has issued a positive Scientific Advice as well as a positive opinion for Orphan Medicinal Product designation for perifosine for multiple myeloma.
Perifosine is also in a Phase 1 trial in pediatric patients, as well as in other Phase 1 and Phase 2 trials for several other tumor types.
Keryx Biopharmaceuticals, Inc. (Keryx) (Nasdaq:KERX – News) is Aeterna Zentaris’ partner and licensee for perifosine in the United States, Canada and Mexico. Perifosine is also out-licensed to Handok for South Korea, while Aeterna Zentaris retains rights for the rest of the world.
About AEZS-108
AEZS-108, a doxorubicin LHRH receptor targeted conjugate, is currently in a Phase 2 trial in advanced ovarian and endometrial cancer for which final results are expected before year-end. AEZS-108 has been granted orphan-drug designation by the FDA and has received a positive opinion for Orphan Medicinal Product designation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency, for the treatment of ovarian cancer. An IND in the U.S. is in place for the treatment of bladder cancer.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. News releases and additional information are available at www.aezsinc.com.
Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company’s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company’s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are required by a governmental authority or applicable law.
http://finance.yahoo.com/news/Aeterna-Zentaris-Data-on-Lead-prnews-473193775.html?x=0&.v=3
Please remember to do your due diligence. To view our full disclaimer please click here
Cytori Therapeutics (NASDAQ: CYTX) Reports Stem & Regenerative Cells from Body Fat Improve Outcomes in Heart Attack Clinical Trial; Plans Underway for European Multicenter Pivotal Trial
Cytori Therapeutics (NASDAQ: CYTX) Reports Stem & Regenerative Cells from Body Fat Improve Outcomes in Heart Attack Clinical Trial; Plans Underway for European Multicenter Pivotal Trial
The first clinical trial of adipose (fat) tissue-derived stem and regenerative cells for the treatment of heart attacks showed a substantial reduction in the size of injury to the heart, an improvement in the amount of blood supply to the heart muscle, and a corresponding functional improvement in the amount of blood the heart can pump. Based on positive safety and feasibility outcomes, and the biological, physiological and functional effects from this pilot study, plans are underway by Cytori Therapeutics (NASDAQ: CYTX), the trial sponsor, to initiate a European medical device approval study for the Celution® System, the cell processing system used in the study. More detailed information on this study and the results from a separate study in chronic heart disease patients may be found at the following link: cytoritx.presslift.com/cardiacdata.
Six-month results from the 14 patient, double-blind, placebo controlled study, referred to as the APOLLO trial, were reported today by Henrickus J. Duckers, M.D., Ph.D., Interventional Cardiologist, Head of Molecular Cardiology, Thoraxcentre, Erasmus University Hospital and co-Principal Investigator for the trial, at the 7th International Symposium on Stem Cell Therapy & Cardiovascular Innovation in Madrid, Spain. Highlights of the study’s six month outcomes are as follows:
The Celution® System-based procedure could be safely performed in an acute setting with no side effects from cell delivery, and no increase in arrhythmias
The study showed a 13.3% absolute reduction in the left ventricular infarct size (the portion of the heart not receiving blood to support pumping) in the treated group versus 8.2% in the placebo group from baseline to six months, based on blinded assessment of MRI data by an independent core laboratory. These data represent matched-pair analysis and exclude two patients whose follow up MRIs were not available. For the entire cohort of patients, mean infarct size improved from 31.6% at baseline to 15.4% at 6 months in cell-treated patients, and remained unchanged at 24.7% in the placebo group. The relevance of this reduction is that based on published literature, patients with an infarct size below 18% have a significantly lower risk of major adverse cardiac events (MACE) than those who are above this level
There was a 3.5 fold greater improvement in perfusion within the left ventricle in the cell treated group (6.0) compared to the placebo group (1.7), as measured by SPECT Visual Rest Scores (nuclear imaging of the heart)
Ejection fraction was measured by four imaging modalities. The greatest absolute change was found in the SPECT (single photon emission computed tomography) analysis, which showed a 5.7% absolute improvement in the cell treated group (+4.0%) compared to placebo (-1.7%)
“Improvements in infarct size, perfusion and ejection fraction are reflective of improvement in the overall cardiovascular health of a patient,” said Dr. Duckers. “Infarct size in particular, based on emerging consensus by the medical community and literature, is what we believe to be the most important predictor of re-hospitalization for heart failure, subsequent infarct, and death. The outcomes from this study are very exciting and warrant moving into a pivotal trial for European approval.”
“The clinical data from APOLLO is consistent with Cytori’s comprehensive preclinical data, reinforcing that improved blood flow and reduction of infarct size are how these cells are believed to impart benefit,” said Marc H. Hedrick, M.D., president of Cytori. “Compared to other cell sources, adipose tissue, using the Celution® System, is the only approach whereby a patient can access a meaningful number of their own cells at the point-of-care. This is especially critical for heart attack patients, where successful outcomes are dependent on immediate coronary intervention.”
As part of the novel procedure, a small amount of fat tissue was removed from each patient’s abdomen shortly after his or her heart attack. Using a proprietary medical device, the Celution® System, developed by Cytori, stem and regenerative cells were quickly separated from each patient’s fat tissue and concentrated at the point-of-care in the catheter laboratory. The cells were then immediately injected into the patient’s coronary artery. Liposuction, processing, and cell delivery all took place within the same procedure.
The APOLLO study is led by co-Principal Investigators Patrick W. Serruys, MD, PhD, Professor of Interventional Cardiology at the Thoraxcentre, Erasmus University Hospital and Henrickus J. Duckers, M.D., Ph.D., Interventional Cardiologist, Head of Molecular Cardiology, Thoraxcentre, Erasmus University Hospital. Hospital General Universitario Gregorio Marañón in Madrid, led by Francisco F. Avilés M.D., PhD, Professor of Medicine and Chief of Department of Cardiology, also participated in this study.
“We would like to thank the patients, the investigators, and all who collaborated with us on this trial,” added Alex Milstein, M.D., Vice President of Clinical Development at Cytori. “We are working closely with our Notified Body in Europe to finalize the design and protocol for a pivotal heart attack study, which we expect to initiate in late 2010 to early 2011. This will be a European approval study that is expected to range in size from 150 to 250 patients.”
Please remember to do your due diligence. To view our full disclaimer please click here
CYTX- A Stock Pick That Mustn’T Miss!!
CYTX- Put this one on your watch list, Cytori Therapeutics will announce the results of their Chronic Heart Ischemia trials on May 6 & 7th. We feel CYTX could be trading very bullishly up until then, if the results are positive the stocks pps could go orbital! Be ready!!
About Cytori
For the Hottest intraday and premarket stock alerts keep a close eye on a twitter page. “Click the Icon Bellow.”
Please remember to do your due diligence. To view our full disclaimer please click here
Do we have your Attention Now? Our Members Continue to Make Huge Profits!
ABK- We alerted our members at 0.65 then it ran to 1.19! Over a 90% Return!
GETA- We alerted our members at 0.06 a week later she ran to a Monstrous high of 0.20! That’s Over 210%!
EXPU- We alerted our members at 0.055 shortly after this beauty was trading in the low 0.20′s!!
FRHV- We alerted our members at 0.002 then it ran to over 0.15 per share!!
BBI- We alerted our members at 0.289 then this stock soared to 0.60 per share a week later!!
Do we have your attention now? Do not miss our Leading Newsletter, The next Pick could be Huge!! “Click the Link Bellow.”
Do you have a friend thats interested in Trading? Have them sign up for Free Today!
For the Hottest intraday and premarket stock alerts keep a close eye on a twitter page. “Click the Icon Bellow.”
Please remember to do your due diligence. To view our full disclaimer please click here
HIRU is Our Next Big Pick! Grab a Position Early for the Biggest Gains!!
The company’s production grounds cover area of more than 60 acres (approx. 25 hectares) and the company signed a 50-year lease for 7.2 hectares of a mountain in Linchuan.
For the Hottest intraday and premarket stock alerts keep a close eye on a twitter page. “Click the Icon Bellow.”
Please remember to do your due diligence. To view our full disclaimer please click here
What An Explosive Week for Our Subscribers! Members who’ve been following our alerts closely are constantly bringing in HUGE profits!
What An Explosive Week for Our Subscribers! Members who’ve been following our alerts closely are constantly bringing in HUGE profits !!
We’ve been getting a ton of emails lately thanking us for our fantastic work. We greatly appreciate all of the positive feedback from our followers and we look forward to always hearing more!
ABK- Alerted at 0.65 ran to 1.19! Over a 90% Return!
GETA- Alerted at 0.06 Ran to a Monstrous high of 0.20! That’s Over 210%!
BBI- Alerted at 0.289 10 minutes later 0.32’s were being hit for a gain of about 10%!
For the Hottest intraday and premarket stock alerts keep a close eye on a twitter page. “Click the Icon Bellow.”
Please remember to do your due diligence. To view our full disclaimer please click here
IENT- New Upcoming Games to be Released in 2010!! International Expansion Underway!! Must See Video Chart!!
IENT- New Upcoming Games to be Released in 2010!! International Expansion Underway!! Must See Video Chart!!
IENT finished the day up 27% at 0.07 which in turn left a very bullish chart in her wake. This bullishness accompanied by Major News should set things off for weeks to come!
We first mentioned the potential of IENT to our subscribers last fall at 0.01. A few weeks ago we sent out another newsletter on IENT because of the increasing interest and recent activity from the company. Since then IENT rose above its 52 week high to an astonishing pps of 0.12 were it peaked, slowly settling down around 0.05 per share.
Today the excitement Flared again as IENT released Major News late in the afternoon leaving people scrambling for shares!
The evening/ morning should give the Major News plenty of time to circulate. We feel once the word gets out that the attention could increase drastically into the opening bell! Have IENT on your radar!
It’s evident that iEntertainment and Thriller New Media are taking Monumental advancements in creating yet Another Multimillion dollar power house like Microprose had been in the mid 90’s.
The news released today hinted at several upcoming game releases for this year as well as the announcement of their expansion into the international gaming market.
Early in January of this year JW Stealey stated he was rebooting this slumbering beauty. Already IENT has taken major steps towards capturing this $41 billion dollar market! On January 13th, iEntertainment Network acquired Thriller New Media, the following month they announced the release of their first retail game to hit shelves in over five years!
“The game titled WarBirds Dogfights is available for a purchase price of $29.95 at Gamestop, Best Buy, Frye’s, MicroCenter, GoGamer, NewEgg, Hastings, and other retailers including Amazon.com!!”
And that’s only the Tip of the Iceberg!
As of late yesterday afternoon IENT announced several upcoming game releases as well as their expansion into the international gaming market! iEntertainment Network signed a distribution agreement with Ant Games of Oxford, United Kingdom, for distribution of Thriller New Media’s current/ new upcoming products into the European market place.
Thriller New Media’s new product release’s for 2010: WarBirds Dogfights, WarBirds Red Baron, and M4 Tank Platoon.
Link to the Yesterday Afternoons Major Press Release:
http://finance.yahoo.com/news/Thriller-New-Media-Partners-bw-3265901479.html?x=0&.v=1
IENT is certainly taking Giant Leaps towards Stardom in this $41 Billion Dollar Market!!
Interesting Fact About Our CEO:
Wild Bill Stealey has (with a great bunch of other folks, to be sure!) created and launched best-selling game titles like F-15 Strike Eagle, F-117A Stealth Fighter, Gunship, Silent Service, Tom Clancy’s Red Storm Rising (the game), Pirates!, Railroad Tycoon, Civilization and many more.
Technical Analysis Video Chart
Please remember to do your due diligence. To view our full disclaimer please click here
